General discussion, page-285

Hi Dalts - it would be highly unusual in my experience for a Company to telegraph what strategy they may employ post trials. I think they would evaluate it on a product by product basis. For example, they may license, sell off, spin out, manufacture, merge - any number of possibilities and also depending on whether it is the Apnea, ARDS, concussion etc.... health solution. Also noting that a lot depends on third party players, margins, global distribution etc... One thing I can say, the IHL Board are very savvy Corporate guys and are heavily invested in maximum return.

Just to describe the supply chain, Valens is an OEM. They are B to B and do not retail but manufacture for others. Cannvalate is a prescriber and they don't produce any products. They dispense. The actual product brand is what is sold - as in Incannex for IHL products. As I said, it wouldn't surprise me that they would use them as the primary source of supply/manufacture.